Citations

Clear

4610 citation(s) found for "Lu, Brian".

The Cessation of Continuous Spike Wave in Slow-Wave Sleep Following a Temporal Lobectomy
Moseley, Brian D. , Dhamija, Radhika , Wirrell, Elaine , Dhamija, Radhika

Mayo Clinic

Journal of Child Neurology | August 24, 2011 | Volume: 27 | Issue: 1 | Pages: 113-116

10.1177/0883073811414708 | PMID 21862835 Get It

The role of surgery in continuous spike wave in slow-wave sleep has not been robustly explored. The authors present a case of an 11-year-old boy with refractory partial seizures and continuous spike wave in slow-wave sleep who was treated with an anterior temporal lobectomy. His presurgical brain magnetic resonance imaging revealed right basal ganglia and thalamic infarcts and right mesial temporal sclerosis. Following surgery, he achieved seizure freedom, cessation of continuous spike wave in slow-wave sleep, and improved cognition. This case provides further evidence that epilepsy syndromes with generalized electrographic discharges can be secondary to focal pathology and potentially cured with resective surgery. The normalization of his sleep electroencephalogram following the anterior temporal lobectomy suggests that temporal lobe structures may be involved in the seizure network needed to generate continuous spike wave in slow-wave sleep.
Primary intramedullary spinal cord lymphoma
Flanagan, Eoin P. , Porter, Alyx B. , Haberman, Thomas M, O’Neill, Brian Patrick , Lanzino, Giuseppe , Keegan, B. Mark , Flanagan, E P

Mayo Clinic

Neurology | August 11, 2011 | Volume: 77 | Issue: 8 | Pages: 784-791

10.1212/wnl.0b013e31822b00b9 | PMID 21832220 Get It

Does detection of anti-AQP4 antibodies trump clinical criteria for neuromyelitis optica?
Weinshenker, Brian G. , Carroll, William M. , Weinshenker, Brian G

Mayo Clinic

Neurology | August 4, 2011 | Volume: 77 | Issue: 9 | Pages: 812-813

10.1212/wnl.0b013e31822b012a | PMID 21813783 Get It

Upper Extremity and Digital Replantation
Maricevich, Marco , Carlsen, Brian T. , Mardini, Samir , Moran, Steven L.

Mayo Clinic

HAND | August 3, 2011 | Volume: 6 | Issue: 4 | Pages: 356-363

10.1007/s11552-011-9353-5 | PMID 23204960 Get It

Digital replantation has become a well-established technique among reconstructive hand surgeons. Numerous replantation centers around the world have published series with impressive survival rates. The ultimate goal of replantation is the restoration of normal hand or digital function; thus, replantation success is not solely related to the outcome of the microvascular anastomosis, but also to the adequacy of bone, tendon, skin, and nerve repairs. In this manuscript, we review the literature on upper extremity and digital replantation from its historical background to current surgical outcomes, outlining surgical indications and contraindications, and the preoperative, operative, and postoperative management of these patients.
Assessment of cognition in early dementia
Silverberg, Nina, Ryan, Laurie, Petersen, Ronald C. , Posner, Holly, Hilsabeck, Robin C. , Rizzo, Albert, Ott, Brian R. , Albert, Marilyn S. , Wagster, Molly V., Schinka, John A., Cullum, C. Munro , Farias, Sarah Tomaszewski , Balota, David A., Budson, Andrew E. , Strutt, Adriana M. , Gollan, Tamar H. , Babcock, Debra, Kramer, Joel H. , Carrillo, María C. , Sperling, Reisa Anne , Snyder, Peter J. , Gallagher, Michela , Raber, Jacob , Possin, Katherine L. , King, Jonathan W. , Kaye, Jeffrey , Rao, Stephen M. , Loewenstein, David , Brandt, Jason , Manly, Jennifer J. , Barnes, Lisa L. , Ganguli, Mary , Litvan, Irene , Ferman, Tanis J.

Mayo Clinic

Alzheimer's & Dementia | July 25, 2011 | Volume: 7 | Issue: 3 | Pages: No page available

10.1016/j.jalz.2011.05.001 | PMID 23559893 Get It

Better tools for assessing cognitive impairment in the early stages of Alzheimer's disease (AD) are required to enable diagnosis of the disease before substantial neurodegeneration has taken place and to allow for detection of subtle changes in the early stages of progression of the disease. The National Institute on Aging and the Alzheimer's Association convened a meeting to discuss state‐of‐the art methods for cognitive assessment, including computerized batteries, as well as new approaches in the pipeline. Speakers described research using novel tests of object recognition, spatial navigation, attentional control, semantic memory, semantic interference, prospective memory, false memory, and executive function as among the tools that could provide earlier identification of individuals with AD. In addition to early detection, there is a need for assessments that reflect real‐world situations so as to better assess functional disability. It is especially important to develop assessment tools that are useful in ethnically, culturally, and linguistically diverse populations as well as in individuals with neurodegenerative disease other than AD.
Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemia
Maurer, Matthew J. , Cerhan, James R. , Katzmann, Jerry A., Link, Brian K. , Allmer, Cristine, Call, Timothy G. , Rabe, Kari G. , Hanson, Curtis A. , Zent, Clive S. , Kay, Neil E. , Slager, Susan L. , Witzig, Thomas E. , Shanafelt, Tait D. , Chaffee, Kari G. , Maurer, Matthew , Cerhan, James R , Link, Brian K

Mayo Clinic

Blood | July 16, 2011 | Volume: 118 | Issue: 10 | Pages: 2821-2826

10.1182/blood-2011-04-349134 | PMID 21765023 Get It

AbstractFree light chains (FLCs) are the most commonly detected paraproteins in chronic lymphocytic leukemia (CLL). We examined the types of FLC abnormalities and prognostic utility of the FLC assay compared with standard prognostic biomarkers in a prospective cohort of 339 patients with newly diagnosed CLL. Three types of FLC abnormalities were identified: monoclonal elevated FLC (elevated κ and/or λ with abnormal FLC ratio), polyclonal elevated FLC (elevated κ and/or λ with normal FLC ratio), and ratio-only FLC abnormality (normal range κ and λ with abnormal FLC ratio). One hundred sixty-five patients (49%) had a FLC abnormality with approximately equal distribution among monoclonal elevation, polyclonal elevation, and ratio-only abnormality. All FLC abnormalities were associated with poor time to first treatment: monoclonal FLC (hazard ratio [HR], 4.99; 95% confidence interval [CI], 2.94-8.48), polyclonal FLC (HR, 2.40; 95% CI, 1.24-4.64), ratio-only FLC (HR, 2.57; 95% CI, 1.40-4.69). Monoclonal FLC and polyclonal FLC were associated with poor overall survival compared with patients with normal FLC. Results remained significant after adjusting for Rai stage. The FLC assay is a simple, widely available clinical test with similar prognostic utility as routinely used prognostic biomarkers for CLL. Among persons with FLC abnormalities, the type of abnormality affects prognostic significance.
Nodular enhancement within the internal auditory canal following retrosigmoid vestibular schwannoma resection: a unique radiological pattern
Carlson, Matthew L. , Abel, Kathryn M. Van , Schmitt, William R., Driscoll, Colin L. W., Neff, Brian A., Lane, John I. , Link, Michael J. , Van Abel, Kathryn M

Mayo Clinic

Journal of Neurosurgery | July 8, 2011 | Volume: 115 | Issue: 4 | Pages: 835-841

10.3171/2011.6.jns11772 | PMID 21740115 Get It

Object The authors describe the unique occurrence of nodular enhancement within the fundus of the internal auditory canal (IAC) lateral to the preoperative radiological tumor margin following gross-total vestibular schwannoma (VS) resection. Methods The nature of the study was a retrospective chart review of records. The authors reviewed the cases of all patients who underwent microsurgical resection of a VS between January 2000 and January 2010 at a single tertiary referral center. Patients with incomplete resection, neurofibromatosis Type 2, and those with fewer than 2 postoperative MR images available for review were excluded. Postsurgical patients with IAC enhancement located lateral to the preoperative imaging–delineated tumor margin were identified. Lesion morphology was characterized on serial MR imaging studies. Clinical follow-up and outcomes were recorded. Results Over the past decade, 350 patients underwent microsurgical VS resection. Of these, 16 patients met study criteria and were found to have postsurgical enhancement in the distal aspect of the IAC lateral to the imaging limits of the preoperative tumor margin on the first postoperative MR imaging study (37.5% women, median age 45 years). Initial MR imaging was performed at a mean of 3.1 months following surgery, and the mean radiological follow-up duration was 39.8 months (range 16.4–101.9 months). None of the 16 patients developed recurrence during the follow-up course. Conclusions In contrast to previous publications that have reported a high rate of recurrence in cases involving nodular enhancement within the original tumor bed, postoperative enhancement in the IAC lateral to the original tumor margin appears to carry much less risk for tumor recurrence. These findings may be helpful when counseling patients on the recommended frequency of postoperative follow-up imaging.
Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas
Micallef, Ivana N. , Ansell, Stephen M. , Link, Brian K. , Inwards, David J. , Porrata, Luis F. , Johnston, Patrick B. , Nowakowski, Grzegorz S. , Thompson, Carrie A. , Allmer, Cristine, Maurer, Matthew J. , Weiner, George J. , Hohl, R.J., Kurtin, Paul J. , Ding, Husheng, Loegering, David A., Schneider, Paula A., Peterson, Kevin, Witzig, Thomas E. , Tang, Hui Jun , Colgan, Joseph P. , Markovic, Svetomir N. , Gupta, Mamta , Habermann, Thomas M. , Kaufmann, Scott H. , Maurer, Matthew , Link, Brian K , Weiner, George

Mayo Clinic

Blood | July 4, 2011 | Volume: 118 | Issue: 18 | Pages: 4882-4889

10.1182/blood-2011-02-334904 | PMID 21725056 Get It

AbstractA phase 2 study of the oral farnesyltransferase inhibitor tipifarnib was conducted in 93 adult patients with relapsed or refractory lymphoma. Patients received tipifarnib 300 mg twice daily on days 1-21 of each 28-day cycle. The median number of prior therapies was 5 (range, 1-17). For the aggressive B-cell, indolent B-cell, and T-cell and Hodgkin lymphoma (HL/T) groups, the response rates were 17% (7/42), 7% (1/15), and 31% (11/36), respectively. Of the 19 responders, 7 were diffuse large B-cell non-Hodgkin lymphoma (NHL), 7 T-cell NHL, 1 follicular grade 2, and 4 HL. The median response duration for the 19 responders was 7.2 months (mean, 15.8 months; range, 1.8-62), and 5 patients in the HL/T group are still receiving treatment at 29-64+ months. The grade 3/4 toxicities observed were fatigue and reversible myelosuppression. Correlative studies suggest that Bim and Bcl-2 should be examined as potential predictors of response in future studies. These results indicate that tipifarnib has activity in lymphoma, particularly in heavily pretreated HL/T types, with little activity in follicular NHL. In view of its excellent toxicity profile and novel mechanism of action, further studies in combination with other agents appear warranted. This trial is registered at www.clinicaltrials.gov as #NCT00082888.
Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma
Micallef, Ivana N. , Maurer, Matthew J. , Wiseman, Gregory A., Nikcevich, Daniel A., Kurtin, Paul J. , Cannon, Michael W., Pérez, Domingo G., Soori, Gamini S. , Link, Brian K. , Habermann, Thomas M. , Witzig, Thomas E. , Maurer, Matthew , Link, Brian K

Mayo Clinic

Blood | June 15, 2011 | Volume: 118 | Issue: 15 | Pages: 4053-4061

10.1182/blood-2011-02-336990 | PMID 21673350 Get It

AbstractApproximately 60% of patients with diffuse large B-cell non-Hodgkin lymphoma (DLBCL) are curable with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemoimmunotherapy. Epratuzumab (E) is an unlabeled anti-CD22 monoclonal antibody with efficacy in relapsed DLBCL. This phase 2 trial tested the safety and efficacy of combining E with R-CHOP (ER-CHOP) in untreated DLBCL. A secondary aim was to assess the efficacy of interim positron emission tomography (PET) to predict outcome in DLBCL. Standard R-CHOP with the addition of E 360 mg/m2 intravenously was administered for 6 cycles. A total of 107 patients were enrolled in the study. Toxicity was similar to standard R-CHOP. Overall response rate in the 81 eligible patients was 96% (74% CR/CRu) by computed tomography scan and 88% by PET. By intention to treat analysis, at a median follow-up of 43 months, the event-free survival (EFS) and overall survival (OS) at 3 years in all 107 patients were 70% and 80%, respectively. Interim PET was not associated with EFS or OS. Comparison with a cohort of 215 patients who were treated with R-CHOP showed an improved EFS in the ER-CHOP patients. ER-CHOP is well tolerated and results appear promising as a combination therapy. This study was registered at www.clinicaltrials.gov as #NCT00301821.